216 related articles for article (PubMed ID: 19623023)
1. Contrast enhanced sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine A to everolimus.
Kihm LP; Hinkel UP; Michael K; Sommerer C; Seckinger J; Morath C; Zeier M; Schwenger V
Transplantation; 2009 Jul; 88(2):261-5. PubMed ID: 19623023
[TBL] [Abstract][Full Text] [Related]
2. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients.
Seckinger J; Sommerer C; Hinkel UP; Hoffmann O; Zeier M; Schwenger V
J Hypertens; 2008 Nov; 26(11):2213-9. PubMed ID: 18854763
[TBL] [Abstract][Full Text] [Related]
3. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
4. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation.
Gude E; Gullestad L; Arora S; Simonsen S; Hoel I; Hartmann A; Holdaas H; Fiane AE; Geiran OR; Andreassen AK
J Heart Lung Transplant; 2010 Jun; 29(6):641-7. PubMed ID: 20304681
[TBL] [Abstract][Full Text] [Related]
5. Acute effects of calcineurin inhibitors on kidney allograft microperfusion visualized by contrast-enhanced sonography.
Kihm LP; Blume C; Seckinger J; Hankel V; Stoffler D; Morath C; Zeier M; Schwenger V
Transplantation; 2012 Jun; 93(11):1125-9. PubMed ID: 22470107
[TBL] [Abstract][Full Text] [Related]
6. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.
Legendre C; Brault Y; Morales JM; Oberbauer R; Altieri P; Riad H; Mahony J; Messina M; Pussell B; Martínez JG; Lelong M; Burke JT; Neylan JF;
Clin Transplant; 2007; 21(3):330-6. PubMed ID: 17488381
[TBL] [Abstract][Full Text] [Related]
8. Complete switch to everolimus in long-term kidney transplants: evolution of the renal function.
Fernández A; Marcén R; Galeano C; Caldés S; Amezquita Y; Villafruela J; Pascual J; Burgos J; Rodríguez-Mendiola N; Ortuño J
Transplant Proc; 2009; 41(6):2345-7. PubMed ID: 19715915
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
Roos M; Liu S; Strobl M; Schmaderer C; Baumann M; Heemann U; Lutz J
Transplant Proc; 2008 Dec; 40(10):3731-6. PubMed ID: 19100477
[TBL] [Abstract][Full Text] [Related]
10. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
11. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A.
Pape L; Ahlenstiel T; Ehrich JH; Offner G
Pediatr Transplant; 2007 May; 11(3):291-5. PubMed ID: 17430485
[TBL] [Abstract][Full Text] [Related]
12. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
Krüger B; Fischereder M; Jauch KW; Graeb C; Hoffmann U; Böger CA; Banas B; Obed A; Schlitt HJ; Krämer BK
Transplant Proc; 2007 Mar; 39(2):518-21. PubMed ID: 17362772
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine versus everolimus: effects on the glomerulus.
Baas MC; Kers J; Florquin S; de Fijter JW; van der Heide JJ; van den Bergh Weerman MA; ten Berge IJ; Bemelman FJ
Clin Transplant; 2013; 27(4):535-40. PubMed ID: 23795805
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitors: do they help preserve renal function?
Moro J; Almenar L; Martínez-Dolz L; Agüero J; Rueda J; Arnau MA; Izquierdo M; Cano O; Sánchez-Lázaro I; Salvador A
Transplant Proc; 2007 Sep; 39(7):2135-7. PubMed ID: 17889116
[TBL] [Abstract][Full Text] [Related]
15. [Slowing progression of chronic allograft nephropathy by conversion from cyclosporin A to tacrolimus].
Peng LK; Xie XB; Peng FH; Wang Y; Jiang Y; Lan GB; Fang CH; Nie MH
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):59-62. PubMed ID: 17344588
[TBL] [Abstract][Full Text] [Related]
16. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
17. Preservation of renal function after heart transplantation: initial single-center experience with sirolimus.
De Meester JM; Van Vlem B; Walravens M; Vanderheyden M; Verstreken S; Goethals M; Kerre N; Wellens F
Transplant Proc; 2005 May; 37(4):1835-8. PubMed ID: 15919481
[TBL] [Abstract][Full Text] [Related]
18. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus.
Oberbauer R
Transplantation; 2009 Apr; 87(8 Suppl):S7-10. PubMed ID: 19384186
[TBL] [Abstract][Full Text] [Related]
19. Everolimus plus dosage reduction of cyclosporine in cardiac transplant recipients with chronic kidney disease: a two-year follow-up study.
Fuchs U; Zittermann A; Hakim-Meibodi K; Börgermann J; Schulz U; Gummert JF
Transplant Proc; 2011 Jun; 43(5):1839-46. PubMed ID: 21693287
[TBL] [Abstract][Full Text] [Related]
20. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
Tedesco-Silva H; Vitko S; Pascual J; Eris J; Magee JC; Whelchel J; Civati G; Campbell S; Alves-Filho G; Bourbigot B; Garcia VD; Leone J; Esmeraldo R; Rigotti P; Cambi V; Haas T;
Transpl Int; 2007 Jan; 20(1):27-36. PubMed ID: 17181650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
